Aura Biosciences, Inc. Increase (Decrease) in Other Noncurrent Assets
Aura Biosciences, Inc. (AURA) reported Increase (Decrease) in Other Noncurrent Assets of $668.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-11
- Aura Biosciences, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was $622.00K, a 236.22% increase year-over-year.
- Aura Biosciences, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was $46.00K.
- Aura Biosciences, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $194.00K, a 60.81% decline year-over-year.
- Aura Biosciences, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $92.00K.
- Aura Biosciences, Inc. increase (decrease) in other noncurrent assets for fiscal 2025 was -$47.00K, a 622.22% decline from fiscal 2024.
- Aura Biosciences, Inc. increase (decrease) in other noncurrent assets for fiscal 2024 was $9.00K, a 89.53% decline from fiscal 2023.
- Aura Biosciences, Inc. increase (decrease) in other noncurrent assets for fiscal 2023 was $86.00K, a 79.67% decline from fiscal 2022.
- Aura Biosciences, Inc. increase (decrease) in other noncurrent assets for fiscal 2022 was $423.00K.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $622.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $668.00K 10-Q · filed 2026-08-11 | $862.00K derived: sum of 3 quarters · filed 2026-08-11 | $954.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $46.00K 10-Q · filed 2026-05-11 | $240.00K derived: sum of 2 quarters · filed 2026-05-11 | $332.00K derived: sum of 3 quarters · filed 2026-05-11 | $517.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $286.00K derived: sum of 2 quarters · filed 2026-03-30 | $471.00K derived: sum of 3 quarters · filed 2026-08-11 | -$47.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $277.00K derived: sum of 2 quarters · filed 2026-08-11 | -$241.00K 10-Q · filed 2025-11-13 | $254.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $185.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$333.00K 10-Q · filed 2026-08-11 | $162.00K derived: sum of 3 quarters · filed 2026-08-11 | -$259.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$518.00K 10-Q · filed 2026-05-11 | -$23.00K derived: sum of 2 quarters · filed 2026-05-11 | -$444.00K derived: sum of 3 quarters · filed 2026-05-11 | -$453.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $495.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $74.00K derived: sum of 2 quarters · filed 2026-03-30 | $65.00K derived: sum of 3 quarters · filed 2026-03-30 | $9.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$421.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$430.00K derived: sum of 2 quarters · filed 2025-11-13 | -$486.00K 10-Q · filed 2025-11-13 | -$662.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$65.00K 10-Q · filed 2025-08-13 | -$241.00K derived: sum of 3 quarters · filed 2025-08-13 | -$256.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$56.00K 10-Q · filed 2025-05-15 | -$232.00K derived: sum of 2 quarters · filed 2025-05-15 | -$247.00K derived: sum of 3 quarters · filed 2025-05-15 | -$170.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$191.00K derived: sum of 2 quarters · filed 2025-03-24 | -$114.00K derived: sum of 3 quarters · filed 2025-03-24 | $86.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $62.00K derived: sum of 2 quarters · filed 2024-11-12 | $262.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $77.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $277.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $200.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $423.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |